David McAvoy

David McAvoy joins Brickell Biotech as General Counsel. Prior to this, Dave served as General Counsel, Vice President and Chief Compliance Officer for the nuclear medicine and oncology biotech Endocyte, Inc., helping it to be acquired successfully by Novartis AG for $2.1 billion in December 2018.

Before Endocyte, Mr. McAvoy was at Eli Lilly and Company for 27 years including as General Counsel of Lilly Emerging Markets – at the time, a $3 billion company division – and most recently there in an executive management business role running strategic alliances for the food animal production group at Lilly’s former Elanco Animal Health subsidiary, now spun off. Also at Lilly, Mr. McAvoy was lead counsel for several iconic medicines, including Prozac® for depression, Gemzar® for pancreatic and lung cancers, and ReoPro®, one of the first interventional cardiology agents. While there he partnered with FDA to create important policy precedents in orphan drug, direct-to-consumer advertising of pharmaceuticals, and clinical trial transparency that influence the industry favorably today.

Mr. McAvoy earned a J.D. and Master of Science in Environmental Science with highest honors from Indiana University, and a B.A. in political science from the University of Notre Dame. He serves on the Board of Directors for The Villages of Indiana, Inc., championing families for abandoned and abused children.